J. Trefler

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial

R. Westhovens, V. Zhdan, P. Wiland, 2020, Rheumatology.

THU0373 Retrospective Analysis of the Safety of Zoledronic Acid in Patients with Osteoporosis in the Course of Connective Tissue Diseases Compared to Patients with Postmenopausal Osteoporosis.

M. Wisłowska, B. Jaszczyk, J. Trefler, 2013 .

Association between IL‐17F Gene Polymorphisms and Susceptibility to and Severity of Rheumatoid Arthritis (RA)

S. Maśliński, A. Paradowska-Gorycka, B. Wojciechowska, 2010, Scandinavian journal of immunology.

Bone tissue metabolism in men with ankylosing spondylitis.

M. Brzosko, J. Łącki, P. Hrycaj, 2011, Advances in medical sciences.

Interleukin‐10 gene promoter polymorphism in Polish rheumatoid arthritis patients

A. Paradowska-Gorycka, J. Łącki, J. Trefler, 2010, International journal of immunogenetics.

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

D. Furst, E. Keystone, P. Klimiuk, 2021, Arthritis Research & Therapy.

Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?

P. Hrycaj, I. Korczowska, A. Olewicz-Gawlik, 2008, Clinical Rheumatology.

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

D. Furst, P. Klimiuk, J. Kay, 2021, Rheumatology.

Reaktywne formy tlenu - znaczenie w fizjologii i stanach patologii organizmu Reactive oxygen species - physiological and pathological function in the human body

I. Wawer, J. Trefler, Ewa Matyska-Piekarska, 2007 .